Mr. Dean Curtis announces that he, and an entity which he controls, have acquired from the treasury of Oncolytics Biotech Inc. (“Oncolytics”), an aggregate of 1,600,000 common shares (the “Shares”) of Oncolytics and warrants (“Warrants”) exercisable to acquire an additional 800,000 common shares. As a result of the acquisition of the Shares and the Warrants, Mr. Curtis owns or controls anaggregate of 1,600,000 common shares of Oncolytics or approximately 11.7% of the issued and outstanding common shares prior to exercise of the Warrants or 16.6% following exercise of all ofthe Warrants.

The Shares and Warrants were acquired for investment purposes through the exercise of previously acquired special warrants and pursuant to Oncolytics’ prospectus dated October 28, 1999.

Mr. Curtis has no present intention to increase his ownership of Oncolytics other than through the potential exercise of the Warrants.